Trial · NCT05123131
Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma
NCT05123131, Phase 2, Active not recruiting, Cancer Trials Ireland
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma. Trials, record NCT05123131. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05123131
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma
- NCT number
- NCT05123131
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 54 participants, actual
- Lead sponsor
- Cancer Trials Ireland
- Conditions
- Multiple Myeloma
- Interventions
- Isatuximab, Bortezomib, Lenalidomide, Dexamethasone (IV)
- First posted
- 2021-11-17
- Last updated
- 2025-07-08
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To evaluate the Very Good Partial Response (VGPR) or better rate by the end of two cycles of induction treatment | 84 days | To evaluate the Very Good Partial Response (VGPR) or better rate by the end of two cycles of induction treatment, defined as the proportion of patients who have achieved VGPR, according to International Myeloma Working Group (IMWG) criteria, by the end of two cycles of induction treatment. |
| Secondary | To evaluate complete response (CR) and sCR rate following one year and two years of maintenance therapy. | 3.5 years | |
| Secondary | To evaluate overall response rate and rate of very good partial response (VGPR) or better following one year of maintenance therapy. | 3.5 years | |
| Secondary | To evaluate time to VGPR or better. | 3.5 years | |
| Secondary | To assess negative minimal residual disease (MRD) rate following ASCT and after 1 and 2 years of maintenance treatment. | 3.5 years | |
| Secondary | To evaluate clinical outcomes including time to progression (TTP). | 3.5 years | |
| Secondary | To evaluate clinical outcomes including progression-free survival (PFS). | 3.5 years | |
| Secondary | To evaluate clinical outcomes including overall survival (OS). | 3.5 years | |
| Secondary | To evaluate clinical outcomes including duration of response (DOR). | 3.5 years | |
| Secondary | To assess the safety of the Isa-RVD treatment regime based on reported adverse events and toxicity. | 3.5 years |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05123131
GET https://conductscience.org/api/trials/v1/NCT05123131/registered